Feb 4 (Reuters) - Pfizer Inc PFE.N:
PFIZER REPORTS STRONG FULL-YEAR 2024 RESULTS AND REAFFIRMS 2025 GUIDANCE
PFIZER: ON TRACK TO DELIVER OVERALL NET COST SAVINGS OF APPROXIMATELY $4.5 BILLION BY END OF 2025
PFIZER: REMAIN CONFIDENT IN OUR ABILITY TO RETURN TO PRE-PANDEMIC OPERATING MARGINS IN COMING YEARS
PFIZER: FOURTH-QUARTER 2024 COMIRNATY REVENUE OF $3.4 BILLION
PFIZER: FOURTH-QUARTER 2024 PAXLOVID REVENUE OF $727 MILLION
FY2025 EARNINGS PER SHARE VIEW $2.93 -- LSEG IBES DATA
FY2025 REVENUE VIEW $63.01 BILLION -- LSEG IBES DATA
PFIZER -TOTAL NON-CASH INTANGIBLE ASSET IMPAIRMENT CHARGES OF $2.9 BILLION TAKEN IN Q4 2024 DUE TO CHANGES IN DEVELOPMENT PLANS
Source text: ID:nBw3tRr7Da
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.